anti-atherosclerotic

YM-750 is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC50 value of 0.18 μM. ACAT is an enzyme that catalyzes the conversion of cholesterol and long-chain fatty-acyl-coenzyme A into cholesteryl esters.

LDL-IN-3 shows anti-atherosclerotic and antioxidant activities.

Orlistat (Tetrahydrolipstatin) is a lipase inhibitor and a fatty acid synthase (FASN) inhibitor. Orlistat has been shown to promote weight loss.

Benzyl isothiocyanate (Benzoylthiocarbimide) (BITC) is an isothiocyanate originally found in cruciferous vegetables. It shows immunomodulatory, anti-parasitic, antibiotic, antioxidative, anti-atherosclerotic, anti-angiogenic, anti-metastatic, anticancer chemotherapeutic, and chemopreventive activities.

Daidzin (Daidzoside) is an isoflavone isolated from soya bean with anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.

L-Arginine (L-Arg) is a substrate of endothelial nitric oxide synthase (eNOS). L-Arginine is transported to vascular smooth muscle cells via a family of cationic amino acid transporters and is metabolized to nitric oxide, polyamines, or L-proline. L-Arginine is a potent vasodilator and can be used to induce experimental acute pancreatitis.

Squalene (AddaVax) is an intermediate in cholesterol synthesis. Squalene has a variety of pharmacological properties, such as antilipemic, hepatoprotective, anti-atherosclerotic, cardioprotective, antioxidant, antitumor and antifungal.

GW9508(GW 9508) is a potent and selective agonist for FFA1 (GPR40), stimulates insulin secretion in a glucose-sensitive manner.

Bovinic acid ((9Z,11E)-Octadecadienoic acid) is a conjugated linoleic acid with anticancer and anti-atherosclerotic activity and can be used to study coronary heart disease and obesity in the elderly.

SB-657510 is a urotensin II (UII) receptor (UT) antagonist. The Ki values of UT for human, monkey, cat, rat and mouse were 61, 17, 30, 65 and 56 nM, respectively. SB-657510 plays an anti-inflammatory role by inhibiting UII-induced inflammatory mediators, such as adhesion molecules, in human vascular endothelial cells and upregulation of cytokines and tissue factors. SB 657510 has a therapeutic effect on diabetes-related atherosclerotic disease in diabetic mouse models.

SP-8356 is a potent, orally active inhibitor of cluster of differentiation 147 (CD147),and is an anti-inflammatory synthetic verbenone derivative, with anti-atherosclerotic effects.

Triacsin C (WS 1228A) from Streptomyces aureofaciens is a differential inhibitor of arachidonic acid coenzyme A synthetase and non-specific long-chain acyl-coenzyme A synthetase, with anti-atherosclerotic activity, inhibition of ACSL activity, and inhibition of the accumulation of TAGs into lipid droplets (LDs).Triacsin C has been used to study rotavirus infection and Alzheimer;s disease. Triacsin C is used to study rotavirus infection and Alzheimer;s disease.

Timofibrate, a thiazolidine derivative patented by Italchemi S.p.A.-Istituto Chimico Farmaceutico, possesses anti-atherosclerotic, cholesterol-lowering, and liver-protective properties.

ABCA1 inducer 2 is a non-lipogenic inducer of ABCA1. It increases the expression of ABCA1 by targeting the LXR pathway, thereby reducing lipid accumulation induced by ox-LDL and inhibiting foam cell formation. ABCA1 inducer 2 holds potential as an anti-atherosclerotic agent.

PCSK9 autophagic degrader 2 (W6) is an autophagosome-targeting agent for PCSK9, with a DC50 value of 20.6 nM. It exhibits effects comparable to anti-atherosclerotic treatments and has a binding constant (KD) with LC3B of 2.5 μM.

Pamaqueside is an anti-atherosclerotic agent.

Pactimibe is a ACAT inhibitor. It has anti-atherosclerotic activity.

Patchouli alcohol (Patchoulol) is a naturally occurring tricyclic sesquiterpenoid found in patchouli oil. It is a key bioactive component known for its immunomodulatory, anti-inflammatory, antioxidant, antitumor, antibacterial, anti-atherosclerotic, antiemetic, and sedative properties.

CI 924 is a lipid-lowering drug. CI 924 increased anti-atherosclerotic HDL and decreased VLDL at 600 mg/day.

GYKI-14451 (LY-178207) is a synthetic thrombin tripeptide inhibitor with anti-atherosclerotic activity.

Phosphatidylserine is a naturally occurring phospholipid that comprises 2-10% of total phospholipids in mammals and is enriched in the central nervous system, particularly the retina. It is anionic and found mainly on the inner leaflet of the cell membrane. It is biosynthesized from phosphatidylcholine or phosphatidylethanolamine by phosphatidyl synthase 1 (PSS1) or PSS2, respectively, in the endoplasmic reticulum and can be reversibly converted back by the same enzymes. It can also be irreversibly converted to phosphatidylethanolamine by phosphatidylserine decarboxylase in the mitochondria. Phosphatidylserine binds to T cell immunoglobulin mucin type 1 (TIM-1) and TIM-4 receptors as well as brain-specific angiogenesis inhibitor 1 (BAI1), leading to anti-inflammatory and anti-atherosclerotic effects. It is also a cofactor involved in the activation of various signaling pathways through activation of protein kinase C, neutral sphingomyelinase, and c-Raf-1 protein kinase among others. Phosphatidylserine is externalized during apoptosis by scramblases in the plasma membrane as a signal for phagocytes to engulf the cell. Phosphatidylserines (bovine) is a mixture of bovine phosphatidylserines containing fatty acids with variable chain lengths at the sn-1 and sn-2 positions.

Pitavastatin (NK-104) is a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, effectively inhibiting cholesterol synthesis from acetic acid in HepG2 cells with an IC50 of 5.8 nM. It also induces hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptors and exhibits therapeutic activities such as anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective, and reno-protective effects.

Dihydroberberine has anti-atherosclerotic, anti-inflammatory, hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.

Pitavastatin-d4 Sodium Salt is a deuterated compound of Pitavastatin Sodium Salt. Pitavastatin Sodium Salt has a CAS number of 574705-92-3. Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC 50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects [1] [2] [3] [8].